Indaptus Therapeutics, Inc. (INDP) is a Healthcare stock trading at $1.28 (as of 2026-08-21), with a market capitalization of $170.55M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
| Price | $1.28 |
| Market Cap | $170.55M |
| Price / Book | 15.00 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
| Top Institutional Holder | VANGUARD GROUP INC ($140946.00) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | David Elliot Lazar |
| Employees | 7 |
| Country | US |
| IPO Date | 2015-08-04 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.